Canine leishmaniasis is an infectious process caused by protozoan parasites of the genus Leishmania. It is a zoonosis, the domestic dog being the main reservoir for human beings. It has become a public concen in Southem European countries, due to concomitant infections with the AIDS virus (HIV). Control of leishmaniasis is difficult because a vaccine has not been developed, and campaigns for the euthanasia of infected animals are both rejected by public opinion and inefficient due to the disease in human beings and mice has been linked to a predominance of either a type TH1 immune response (high production of y-IFN), or a type TH2 response (high production of IL4), respectively. In dogs, a protective immune response has also been linked to a type TH1-like answer. This project will allow us to develop monoclonal antibodies against recombinant canine y-IFN and IL-4 for an ELISA test to be used in the quantification of these cytokines produced by peripheral blood mononuclear cells. RT.PCR techniques for yhe detection and quantifiction of the production of these cytokines will also be developed. Application of these techniques to samples from three distinct dog populations (healthy non-infected dogs, healthy naturally-infected dogs, and naturally infected sick dogs) will enable us to set up a kit for the evaluation of the immune response against Leismania en dogs. In collaboration with a pharmaceutical company, we expect to develop an easy kit to be used in practice. This will allow identification of healthy carriers, and to establish a dependable prediction of the evolution of disease in symptomatic infected dogs.
|Effective start/end date||28/12/00 → 28/12/01|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.